Clinical trial
Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment…
NCT00469183 · Galderma R&D, Industry · Completed
Key facts
| NCT number | NCT00469183 |
|---|---|
| Title | Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma |
| Official title | An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma |
| Lead sponsor | Galderma R&D, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Melasma |
| Intervention type | Drug |
| Interventions | Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05% |
| Enrollment | 70 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | May 4, 2007 |
| Last update posted | Jul 29, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: